Phase 3 N=538 A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Adverse Event (AE) Summary Over Time — 433; 390; 333; 294 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=60 Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site
Neoplasm, Unknown Primary
Primary: Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death — 12.6 months
N/A N=499 A Clinical Study to Evaluate the Use of Episodic, Intensive Blood Glucose Monitoring in Persons With Non-insulin Treated Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) at Month 12 — -0.88; -1.16 Percent — p=0.0416
Phase 1 N=55 Human Pharmacology Trial of Calcium-vitamin D3 Tablet in Healthy Participants
Calcium Deficiency · Vitamin D Deficiency
Primary: Amount of Calcium Excreted in Urine From 0 Hours up to 6 Hours Post Dose (Ca2+ Ae0-6h) — 1.07; 0.63 mmol
Phase 3 N=319 A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment
Chronic Idiopathic Urticaria
Primary: Change From Baseline to Week 12 in the Weekly Itch Severity Score — -3.63; -6.46; -6.66; -9.40 Units on a scale — p=0.0010
Phase 2 N=172 Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
Ocular Hypertension · Glaucoma
Primary: Change From Baseline in Average Eye Intraocular Pressure (IOP) — 25.350; 25.318; 25.341; 24.650 Millimeters of Mercury (mmHg)
Phase 2 N=45 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Precancerous Lesions, Cancer, or Other Disease of the Aerodigestive Tract
Head and Neck Cancer · Precancerous/Nonmalignant Condition
Primary: Number of Patients Achieving Complete or Partial Response 4 Months After Completion of Study Treatment — 32 participants
Phase 3 N=1,011 Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)
Iron Deficiency Anemia
Primary: Mean Increase From Baseline to the Highest Observed Hemoglobin Value Between Baseline and Day 35 or Time of Intervention for Patients Taking FCM as Compared to That for…
Phase 3 N=205 Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine
Meningococcal Disease
Primary: Percentage of Subjects With Persisting Serum Bactericidal Antibody Titers ≥1:8, Upto 13-33 Months After Primary Vaccination With Either MenACWY-CRM or MenC Vaccine — 13…
Phase 2 N=29 A Study in Asymptomatic HIV Infected Patients to Investigate Pharmacodynamics, Pharmacokinetics, Safety and Toleration of UK-453,061
HIV-1
Primary: Change From Baseline in Human Immunodeficiency Virus-1 (HIV-1) Viral Load at Day 8 — 4.57; 4.39; 4.41; 4.38 log10 copies/mL
Phase 2 N=165 Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Average Eye Intraocular Pressure (IOP) — 25.88; 25.18; 25.39; 25.73 Millimeters of Mercury (mmHg)
Phase 3 N=864 Travoprost 3-Month Safety and Efficacy Study
Open-Angle Glaucoma · Ocular Hypertension
Primary: Mean Intraocular Pressure (IOP) at Week 2, Week 6, and Month 3 for Each Assessment Time Point (8 AM, 10 AM, and 4 PM) — 19.4; 19.5; 18.6; 18.6 millimeters mercury (mmHg)
Phase 2 N=9 Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma · Recurrent Metastatic Squamous Neck Cancer With Occult Primary · Recurrent Squamous Cell Carcinoma of the Hypopharynx
Primary: Overall Response Rate — 1; 8 participants
Phase 3 N=277 Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
Pathological Myopia
Primary: Average Change From Baseline to Month 1 Through Month 3 on Visual Acuity of the Study Eye — 55.4; 55.8; 54.7; 66.0 Letters
N/A N=24 Healthy Adult Volunteer Study of Intraosseous Infusion Using the Sternum
Intraosseous Vascular Access
Primary: Occurrences of Extravasation During Infusion — 2 participants